Home Health Dementia - Pipeline Review, H1 2019 - ResearchAndMarkets.com

Dementia – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN – (WIRE OF BUSINESS)–The "Dementia
– Revision of the pipeline, H1 2019 "
drug pipelines have been added ResearchAndMarkets.com of
offer.

Dementia – Pipeline Review, H1 2019 It provides
complete information on developing therapies for
Dementia (central nervous system), complete with stage analysis
development, drug target, mechanism of action (MoA), path of
administration (RoA) and type of molecule.

The guide covers the descriptive pharmacological action of the
therapies, its complete research and development history and the latest
news and press releases.

Also the Dementia pipeline guide (Central nervous system) examines the key
players involved in therapeutic development for dementia and features
dormant and abandoned projects.

The guide covers the therapies being developed by companies
/ Universities / Institutes, the molecules developed by companies in phase
Phases III, Phase II, Phase I, Preclinical, Discovery and Unknown are 5,
17, 20, 48, 17 and 3 respectively.

Similarly, the university portfolio in Phase I, Preclinical and
The discovery stages comprise 1, 10 and 3 molecules respectively.

The driving of dementia gas (Central nervous system) helps to identify
and keeping track of emerging players in the market and in their portfolios,
improves decision-making skills and helps to create effective
counter strategies to gain a competitive advantage.

Purpose:

  • The pipeline guide provides a snapshot of global therapy
    dementia landscape (central nervous system)

  • The pipeline guide examines dementia pipeline therapies (central
    Nervous system) by companies and universities / research institutes
    based on information derived from company and industry-specific sources

  • The pipeline guide covers pipeline products based on different phases of
    development that goes from pre-registration to discovery e
    stages not disclosed

  • The pipeline guide presents descriptive drug profiles for the pipeline
    products that include, product description, descriptive license
    and details of collaboration, R & D brief, MoA and other developmental
    activity

  • The pipeline guide examines the major companies involved in dementia (central
    Nervous system) therapeutic and enlist all their major and minor
    projects

  • The pipeline guide evaluates dementia (central nervous system)
    therapies based on the mechanism of action (MoA), drug target, way
    administration (RoA) and type of molecule

  • The pipeline guide encapsulates all the sleeper and is interrupted
    pipeline projects

  • The pipeline guide examines the latest news on the pipeline
    therapies for dementia (central nervous system)

Topics covered

  1. introduction

  2. Dementia – Overview

  3. Dementia – Therapeutic development

  4. Dementia – Evaluation of therapy

  5. Dementia – Companies involved in therapeutic development

  6. Dementia – Drug Profiles

  7. Dementia – dormant projects

  8. Dementia – Products out of production

  9. Dementia – Milestones on product development

Companies mentioned

  • Acadia Pharmaceuticals Inc

  • Acorda Therapeutics Inc

  • Actinogen Medical Ltd

  • Adamed Sp z oo

  • AgeneBio Inc

  • Alector Inc

  • Allergan Plc

  • Anavex Life Sciences Corp.

  • Asceneuron SA

  • Axon Neuroscience SE

  • Axovant Sciences Ltd

  • Biogen Inc

  • BioXcel Therapeutics Inc

  • Boehringer Ingelheim GmbH

  • Bolder Biotechnology Inc

  • Cortice Biosciences Inc

  • CSPC NBP Pharmaceutical Co Ltd

  • Daewoong Pharmaceutical Co Ltd

  • Denali Therapeutics Inc

  • DiaMedica Therapeutics Inc

  • Dr. August Wolff GmbH & Co KG Arzneimittel

  • Eisai Co Ltd

  • Eli Lilly and Co

  • Ensol Biosciences Inc

  • EVER Neuro Pharma GmbH

  • GW Pharmaceuticals Plc

  • H. Lundbeck AS

  • HSRx Group

  • Hyundai Pharmaceutical Co Ltd

  • Immungenetics AG

  • Ionis Pharmaceuticals Inc

  • IRLAB Therapeutics AB

  • Ironwood Pharmaceuticals Inc

  • Johnson & Johnson

  • M3 Biotechnology Inc

  • MediPost Co Ltd

  • MGC Pharmaceuticals Ltd

  • Neuraltus Pharmaceuticals Inc

  • Neurimmune Holding AG

  • NeuroScientific Biopharmaceuticals Ltd

  • Oryzon Genomics SA

  • Otsuka Holdings Co Ltd

  • P2D Inc

  • Pacific Northwest Biotechnology LLC

  • Pharmasum Therapeutics AS

  • Prana Biotechnology Ltd

  • ProMIS Neurosciences Inc

  • Prothena Corp Plc

  • Resverlogix Corp

  • Rodin Therapeutics Inc

  • and more …

For more information on this drug pipeline report, visit https://www.researchandmarkets.com/research/q68lkb/dementia?w=4

Must Read

Powerball winning numbers for the 20.04.2014: $ 136 million jackpot

The Powerball jackpot on duty on Saturday, April 20, reached an estimated $ 136 million. The one-time cash payment for today's Powerball draw is...

Book tribute to Anthony Bourdain to be released in May

The book's publisher's website says it "brings together memories and anecdotes from fans reminiscent of Bourdain's unique achievements and lasting influence on their...

News from Meghan Markle: Pippa Middleton gives some advice from BABY before the birth of Meghan Royal | news

Pippa first opened her son Arthur since he was born on 15 October last year. Kate, the sister of the Duchess of Cambridge, is...

Chelsea 4-7, Northridge 0-2: Hornets sweep the double-head playoff class 6A

Waiting for a day to play baseball playoffs didn't hurt Chelsea Hornets.The Hornets (20-11) got the extinguishing launch from both of their aces...